Citations (239)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (32)
Xueqin Huang, Li You, Eugenie Nepovimova, Miroslav Psotka, David Malinak, Marian Valko, Ladislav Sivak, Jan Korabecny, Zbynek Heger, Vojtech Adam, Qinghua Wu & Kamil Kuca. (2023) Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK). Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Read now
Pawel Robak & Tadeusz Robak. (2023) Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert Opinion on Biological Therapy 23:1, pages 21-35.
Read now
Read now
Doreen G. Te Raa, Lina van der Straten, Michel van Gelder, Sabina Kersting, Mark-David Levin, Rogier Mous, Hanneke M. van der Straaten, Marten R. Nijziel, Ellen van der Spek, Eduardus F. M Posthuma, Hein P.J Visser, Marjolein van der Klift, Koen de Heer, Mar Bellido, Jeanette K. Doorduijn, Anke H.W Bruns, Reinier A. P Raijmakers & Arnon P. Kater. (2022) Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia & Lymphoma 63:10, pages 2276-2289.
Read now
Read now
Anthony Cahn, J Nicole Hamblin, Jon Robertson, Malcolm Begg, Emily Jarvis, Robert Wilson, Gordon Dear, Claudia Leemereise, Yi Cui, Maki Mizuma, Mickael Montembault, Cedric Van Holsbeke, Wim Vos, Wilfried De Backer, Jan De Backer & Edith M Hessel. (2021) An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1607-1619.
Read now
Read now
Paulina Stefaniuk, Julia Onyszczuk, Agnieszka Szymczyk & Monika Podhorecka. (2021) Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. Cancer Management and Research 13, pages 1459-1476.
Read now
Read now
Thomas A Ollila & Adam J Olszewski. (2021) Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma. Cancer Management and Research 13, pages 3935-3952.
Read now
Read now
Michele Merli, Francesco Passamonti & Luca Arcaini. (2021) The double significance of idelalisib immune-related toxicity. Leukemia & Lymphoma 62:12, pages 2815-2817.
Read now
Read now
Nina D. Wagner-Johnston, Jeff Sharman, Richard R. Furman, Gilles Salles, Jennifer R. Brown, Tadeusz Robak, Lin Gu, Guan Xing, Rebecca J. Chan, Nishanthan Rajakumaraswamy & Ajay K. Gopal. (2021) Idelalisib immune-related toxicity is associated with improved treatment response. Leukemia & Lymphoma 62:12, pages 2915-2920.
Read now
Read now
Liana Nikolaenko, Tingting Liu & Alexey V. Danilov. (2021) Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. Expert Review of Anticancer Therapy 21:5, pages 481-488.
Read now
Read now
Philipp Berning & Georg Lenz. (2021) The role of PI3K inhibitors in the treatment of malignant lymphomas. Leukemia & Lymphoma 62:3, pages 517-527.
Read now
Read now
Thomas D. Rodgers, AnnaLynn M. Williams, Andrea Baran, Patrick M. Reagan, Carla Casulo, Clive S. Zent, Andrew Evans, Jonathan W. Friedberg & Paul M. Barr. (2021) Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 62:3, pages 598-605.
Read now
Read now
Anna Korycka-Wołowiec, Dariusz Wołowiec & Tadeusz Robak. (2020) The safety of available chemo-free treatments for mantle cell lymphoma. Expert Opinion on Drug Safety 19:11, pages 1377-1393.
Read now
Read now
Piotr Smolewski & Dominika Rydygier. (2020) Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies. Expert Opinion on Pharmacotherapy 21:15, pages 1915-1926.
Read now
Read now
Shinichi Makita, Rika Hosoba & Kensei Tobinai. (2020) Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opinion on Drug Safety 19:9, pages 1105-1120.
Read now
Read now
Dirk L. Kienle & Stephan Stilgenbauer. (2020) Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy 21:8, pages 917-929.
Read now
Read now
Elżbieta Iskierka-Jażdżewska & Tadeusz Robak. (2020) Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert Review of Hematology 13:1, pages 39-53.
Read now
Read now
Yandong Shen, Kyle Crassini, Suneet Sandhu, Narjis Fatima, Richard I. Christopherson, Stephen P. Mulligan & O. Giles Best. (2019) Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. Leukemia & Lymphoma 60:7, pages 1632-1643.
Read now
Read now
Christine I. Chen, Harminder Paul, Lisa W. Le, Ellen N. Wei, Susi Snitzler, Trina Wang, Olga Levina, Sumeet Kakar, Anthea Lau, Michelle Queau, James B. Johnston, Deborah A. Smith & Suzanne Trudel. (2019) A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*. Leukemia & Lymphoma 60:1, pages 92-100.
Read now
Read now
Francesca R. Mauro, Maria D. Caputo, Serena Rosati, Sara Pepe, Daniela De Benedittis, Maria L De Luca & Robin Foà. (2018) Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Review of Hematology 11:8, pages 601-611.
Read now
Read now
Caroline Migault, Delphine Lebrun, Olivier Toubas, Yohan Nguyen, Aurélien Giltat, Gautier Julien, Dominique Toubas, François Lebargy, Alain Delmer & Firouzé Bani-Sadr. (2018) Pulmonary adverse events related to idelalisib therapy: A single centre experience. Journal of Chemotherapy 30:5, pages 318-322.
Read now
Read now
Thomas D. Rodgers & Patrick M. Reagan. (2018) Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma. Expert Opinion on Emerging Drugs 23:2, pages 111-122.
Read now
Read now
Tamar Tadmor, Manfred Welslau & Iwona Hus. (2018) A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Review of Hematology 11:1, pages 57-70.
Read now
Read now
Benjamin L. Lampson & Jennifer R. Brown. (2017) PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opinion on Investigational Drugs 26:11, pages 1267-1279.
Read now
Read now
Pawel Robak & Tadeusz Robak. (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:11, pages 1249-1265.
Read now
Read now
Phu N. Tran & Susan O’Brien. (2017) The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Safety 16:9, pages 1079-1088.
Read now
Read now
Max J. Gordon, Lionel D. Lewis, Jennifer R. Brown & Alexey V. Danilov. (2017) Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. Expert Review of Hematology 10:8, pages 707-718.
Read now
Read now
Abdallah Abou Zahr, Prithviraj Bose & Michael J. Keating. (2017) Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 18:9, pages 857-873.
Read now
Read now
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Guang Yang, Lian Xu, Zachary R. Hunter & Steven P. Treon. (2017) Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leukemia & Lymphoma 58:4, pages 1002-1004.
Read now
Read now
Jacqueline C Barrientos. (2016) Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. OncoTargets and Therapy 9, pages 2945-2953.
Read now
Read now
Francesca R. Mauro, Adriano Salaroli, Maria D. Caputo, Gioia Colafigli, Luigi Petrucci, Melissa Campanelli, Antonietta Ferretti, Anna R Guarini & Robin Foà. (2016) Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology 9:12, pages 1165-1175.
Read now
Read now
Solomon A. Graf & Ajay K. Gopal. (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy 17:2, pages 265-274.
Read now
Read now
Andrew Davies. (2015) Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Expert Review of Hematology 8:5, pages 581-593.
Read now
Read now
Articles from other publishers (207)
Stéphane Saint-Georges, Maude Quettier, Marouane Bouyaba, Stéphanie Le Coquil, Vanessa Laurienté, Lionel Guittat, Vincent Lévy, Florence Ajchenbaum-Cymbalista, Nadine Varin-Blank, Christine Le Roy & Dominique Ledoux. (2016) Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia. Oncotarget 7:27, pages 41031-41046.
Crossref
Crossref
Deborah C. Marshall & Zahra Ghiassi-Nejad. 2024. Palliative Radiation Oncology. Palliative Radiation Oncology
367
378
.
V. Koneti Rao, Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A. Dalm, Antonino Trizzino, Yulia Zharankova, Sharon Webster, Alanvin Orpia, Julia Körholz, Vassilios Lougaris, Yulia Rodina, Kath Radford, Jason Bradt, Anurag Relan, Steven M. Holland, Michael J. Lenardo & Gulbu Uzel. (2023) Interim analysis: Open-label extension study of leniolisib for patients with APDS. Journal of Allergy and Clinical Immunology.
Crossref
Crossref
Oluwatobi Odetola & Shuo Ma. (2023) Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Current Hematologic Malignancy Reports 18:5, pages 130-143.
Crossref
Crossref
Jingmei Yang & Ran Friedman. (2023) Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia. Cancer Cell International 23:1.
Crossref
Crossref
Martin Špaček, Lukáš Smolej, Martin Šimkovič, Lucie Nekvindová, Zlatuše Křístková, Yvona Brychtová, Anna Panovská, Stanislava Mašlejová, Lucie Bezděková, Dominika Écsiová, Pavel Vodárek, Jana Zuchnická, Jana Mihályová, Renata Urbanová, Peter Turcsányi, Daniel Lysák, Jan Novák, Martin Brejcha, Tereza Líkařová, Prokop Vodička, Jana Baranová, Marek Trněný & Michael Doubek. (2023) Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). British Journal of Haematology 202:1, pages 40-47.
Crossref
Crossref
Takuya Watanabe. (2023) Recent advances in treatment of nodal and gastrointestinal follicular lymphoma. World Journal of Gastroenterology 29:23, pages 3574-3594.
Crossref
Crossref
Roberta Mazzucato, Marinella Roberti, Anna Maria Capelli, Fabio Rancati, Matteo Biagetti, Claudio Fiorelli, Paolo Bruno, Paolo Ronchi, Serena Bertolini, Mauro Corsi & Daniele Pala. (2023) Application of an “inhalation by design” approach to the identification and in-vitro evaluation of novel purine based PI3Kδ inhibitors. European Journal of Medicinal Chemistry 254, pages 115331.
Crossref
Crossref
John F. Seymour. (2023) Approach to relapsed CLL including Richter Transformation. Hematological Oncology 41:S1, pages 136-143.
Crossref
Crossref
Jun Wei, Dongyan Gu, Leer Yuan & Rong Sheng. (2023) Advances in the Discovery of Novel Inhaled PI3Kδ Inhibitors for the
Treatment of Asthma. Current Medicinal Chemistry 30:17, pages 1971-1992.
Crossref
Crossref
Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Alessandro Bressan, Daniela Bellarosa, Corrado Carrisi, Alessandro Paoli, Mario Bigioni, Patrizia Tunici, Clelia Irrissuto, Massimiliano Salerno, Joaquin Arribas, Elisa de Stanchina, Maurizio Scaltriti & Monica Binaschi. (2023) Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast Cancer Research and Treatment 199:1, pages 13-23.
Crossref
Crossref
Titas Banerjee, Myung Sun Kim, Alyson Haslam & Vinay Prasad. (2023) Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma. JAMA Internal Medicine 183:5, pages 435.
Crossref
Crossref
Claire Breal, Frederic Beuvon, Thibault de Witasse-Thezy, Solene Dermine, Patricia Franchi-Rezgui, Benedicte Deau-Fisher, Lise Willems, Eric Grignano, Adrien Contejean, Didier Bouscary, Jean Luc Faillie, Jean-Marc Treluyer, Corinne Guerin, Laurent Chouchana & Marguerite Vignon. (2023) Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies. Cancers 15:8, pages 2279.
Crossref
Crossref
Malcolm Begg, Augustin Amour, Emily Jarvis, Teresa Tang, Sara Santos Franco, Andrew Want, Misba Beerahee, Disala Fernando, Yakshitha Karkera, Clare Sander, Thomas Southworth, Dave Singh, Jonathan Clark, Sergey Nejentsev, Klaus Okkenhaug, Alison Condliffe, Anita Chandra, Anthony Cahn & Edward Banham Hall. (2023) An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. Pulmonary Pharmacology & Therapeutics 79, pages 102201.
Crossref
Crossref
Benoît Pilmis, Yousra Kherabi, Pauline Huriez, Jean-Ralph Zahar & Djamel Mokart. (2023) Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers 15:7, pages 1989.
Crossref
Crossref
Mazyar Shadman. (2023) Diagnosis and Treatment of Chronic Lymphocytic Leukemia. JAMA 329:11, pages 918.
Crossref
Crossref
Joel McCayandand & John G. Gribben. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
113
129
.
Alessandro Broccoli & Pier Luigi Zinzani. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies
86
101
.
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan & Xiaochun Yang. (2023) Development and safety of PI3K inhibitors in cancer. Archives of Toxicology 97:3, pages 635-650.
Crossref
Crossref
Zhongwang Wang, Hui Zhou, Jing Xu, Jinjin Wang & Ting Niu. (2023) Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Frontiers in Immunology 13.
Crossref
Crossref
Pingxin Zhang, Ren Mao, Chuhan Zhang, Yun Qiu & Minhu Chen. (2023) Gastrointestinal injury induced by immunomodulators: A review article. Therapeutic Advances in Gastroenterology 16, pages 175628482311585.
Crossref
Crossref
Sebastian Faehling, Mariana Coelho, Alessia Floerchinger, Christof Schneider, Stephan Stilgenbauer, Peter Lichter, Martina Seiffert & Philipp M. Roessner. (2023) Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia. HemaSphere 7:3, pages e840.
Crossref
Crossref
Max J. Gordon, Mitchell R. Smith & Loretta J. Nastoupil. (2023) Follicular lymphoma: The long and winding road leading to your cure?. Blood Reviews 57, pages 100992.
Crossref
Crossref
Emily J. Hanan, Marie-Gabrielle Braun, Robert A. Heald, Calum MacLeodConnie Chan, Saundra Clausen, Kyle A. Edgar, Charles Eigenbrot, Richard ElliottNicholas Endres, Lori S. Friedman, Emily Gogol, Xiao-Hui Gu, Rebecca Hong Thibodeau, Philip S. JacksonJames R. Kiefer, Jamie D. KnightMichelle Nannini, Raman NarukullaAmanda Pace, Jodie Pang, Hans E. Purkey, Laurent Salphati, Deepak Sampath, Stephen Schmidt, Steve Sideris, Kyung Song, Swathi Sujatha-Bhaskar, Mark Ultsch, Heidi Wallweber, Jianfeng Xin, SiewKuen YeapAmy Young, Yu Zhong & Steven T. Staben. (2022) Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. Journal of Medicinal Chemistry 65:24, pages 16589-16621.
Crossref
Crossref
Le Yu, Jessica Wei & Pengda Liu. (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology 85, pages 69-94.
Crossref
Crossref
Taylor M Weis, Jillian Gutierrez, Charlene C Kabel, Amber C King, Ryan J Daley & Sarah E Stump. (2022) Real-world management of targeted therapies in chronic lymphocytic leukemia. Journal of Oncology Pharmacy Practice 28:6, pages 1411-1433.
Crossref
Crossref
Geoffrey Shouse, Olga V. Danilova & Alexey V. Danilov. (2022) Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Current Opinion in Oncology 34:5, pages 540-545.
Crossref
Crossref
Manuel Ramos-Casals, Alejandra Flores-Chávez, Pilar Brito-Zerón, Olivier Lambotte & Xavier Mariette. (2022) Immune-related adverse events of cancer immunotherapies targeting kinases. Pharmacology & Therapeutics 237, pages 108250.
Crossref
Crossref
Manuela A. Hoechstetter, Wolfgang Knauf, Silvia Dambacher, Nike Hucke, Kristin Höhne, Anna van Troostenburg, Heribert Ramroth, Wolfgang Abenhardt & Mathias Rummel. (2022) Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany. Clinical Lymphoma Myeloma and Leukemia 22:8, pages e777-e787.
Crossref
Crossref
John M Pagel, Jacob D Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li & Andrew D Zelenetz. (2022) Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. The Lancet Oncology 23:8, pages 1021-1030.
Crossref
Crossref
Weihang Shan, Guixiang Wu, Yueting Huang, Hanyan Zeng, Weilin Xia, Zhijuan Lin & Bing Xu. (2022) Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis. Annals of Hematology 101:8, pages 1741-1753.
Crossref
Crossref
Kapil Gadkar, Christina Friedrich, Vincent Hurez, Maria‐Luisa Ruiz, Leslie Dickmann, Mohit Kumar Jolly, Leah Schutt, Jin Jin, Joseph A. Ware & Saroja Ramanujan. (2021) Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors. CPT: Pharmacometrics & Systems Pharmacology 11:5, pages 616-627.
Crossref
Crossref
Martin F. M. de Rooij, Yvonne J. Thus, Nathalie Swier, Roderick L. Beijersbergen, Steven T. Pals & Marcel Spaargaren. (2022) A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nature Communications 13:1.
Crossref
Crossref
Tianyuan Ci, Wentao Zhang, Yingyu Qiao, Huangjuan Li, Jing Zang, Hongjun Li, Nianping Feng & Zhen Gu. (2022) Delivery strategies in treatments of leukemia. Chemical Society Reviews 51:6, pages 2121-2144.
Crossref
Crossref
Iwona Hus, Bartosz Puła & Tadeusz Robak. (2022) PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. Cancers 14:6, pages 1571.
Crossref
Crossref
Juha Ranti, Katariina Perkonoja, Tommi Kauko, Heidi Loponen, Emmi I. Joensuu & Tiina M. Järvinen. (2021) Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. eJHaem 3:1, pages 291-300.
Crossref
Crossref
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente-Macías, Daniel J. Baillache, Stephen Croke & Asier Unciti-Broceta. (2021) Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry 65:2, pages 1047-1131.
Crossref
Crossref
Victor Yazbeck, Erin Alesi, Jennifer Myers, Mary Helen Hackney, Laurie Cuttino & David A. Gewirtz. 2022. Strategies to Mitigate the Toxicity of Cancer Therapeutics. Strategies to Mitigate the Toxicity of Cancer Therapeutics
1
27
.
Cybele Lara R. Abad & Raymund R. Razonable. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
273
292
.
Matthew S. DavidsOwen A. O’ConnorWojciech Jurczak, Felipe SamaniegoTimothy S. FenskePier Luigi Zinzani, Manish R. Patel, Nilanjan GhoshBruce D. ChesonEnrico DerenziniDanielle M. BranderJames A. ReevesWanda Knopińska-PosłusznyJohn N. Allan, Tycel PhillipsPaolo F. Caimi, Ewa Lech-MarandaJohn M. Burke, Richy AgajanianRuth Pettengell, Lori A. LeslieChan Y. Cheah, Gustavo FonsecaJames EssellJulio C. ChavezJohn M. PagelJeff P. Sharman, Yanzhi HsuHari P. MiskinPeter SportelliMichael S. WeissIan W. Flinn. (2021) Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances 5:23, pages 5332-5343.
Crossref
Crossref
Alessandro Allegra, Alessandro Tonacci, Caterina Musolino, Giovanni Pioggia & Sebastiano Gangemi. (2021) Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Frontiers in Immunology 12.
Crossref
Crossref
Bart Vanhaesebroeck, Matthew W. D. Perry, Jennifer R. Brown, Fabrice André & Klaus Okkenhaug. (2021) PI3K inhibitors are finally coming of age. Nature Reviews Drug Discovery 20:10, pages 741-769.
Crossref
Crossref
Monika D. Scuron, Brittany L. Fay, Andrew J. Connell, Julian Oliver & Paul A. Smith. (2021) The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren’s syndrome. International Immunopharmacology 98, pages 107904.
Crossref
Crossref
Yeon Su Kim, Min Gyeong Cheon, Pulla Reddy Boggu, Su Youn Koh, Gi Min Park, Gahee Kim, Seo Hyun Park, Sung Lyea Park, Chi Woo Lee, Jong Woo Kim & Young Hoon Jung. (2021) Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies. Bioorganic & Medicinal Chemistry 45, pages 116312.
Crossref
Crossref
Kristoffer H. Johansen, Dominic P. Golec, Julie H. Thomsen, Pamela L. Schwartzberg & Klaus Okkenhaug. (2021) PI3K in T Cell Adhesion and Trafficking. Frontiers in Immunology 12.
Crossref
Crossref
Benjamin L. Lampson & Jennifer R. Brown. (2021) The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 35:4, pages 807-826.
Crossref
Crossref
Gian Matteo Rigolin, Francesco Cavazzini, Alfonso Piciocchi, Valentina Arena, Andrea Visentin, Gianluigi Reda, Giulia Zamprogna, Francesca Cibien, Orsola Vitagliano, Marta Coscia, Lucia Farina, Gianluca Gaidano, Roberta Murru, Marzia Varettoni, Rossella Paolini, Paolo Sportoletti, Daniela Pietrasanta, Anna Lia Molinari, Francesca M. Quaglia, Luca Laurenti, Roberto Marasca, Monia Marchetti, Francesca R. Mauro, Enrico Crea, Marco Vignetti, Massimo Gentile, Marco Montillo, Robin Foà & Antonio Cuneo. (2021) Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology 39:3, pages 326-335.
Crossref
Crossref
Klaus Okkenhaug. (2021) How to resist PI3Kδ inhibition: activate MAPK!. Blood 138:1, pages 3-4.
Crossref
Crossref
Toby A. Eyre, Gavin Preston, Huseini Kagdi, Amin Islam, Toby Nicholson, Harry W. Smith, Adam P. Cursley, Heribert Ramroth, Guan Xing, Lin Gu, Nishanthan Rajakumaraswamy & Christopher Fegan. (2021) A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel). British Journal of Haematology 194:1, pages 69-77.
Crossref
Crossref
Matthew W. D. Perry, Karin Björhall, Peter Bold, Mikael Brűlls, Ulf Börjesson, Johan Carlsson, Hui-Fang Amy Chang, Yunhua Chen, Anders Eriksson, Britt-Marie Fihn, Rebecca Fransson, Linda Fredlund, Hongbin Ge, Haijuan Huang, Kostas Karabelas, Eva Lamm Bergström, Sarah Lever, Helena Lindmark, Mickael Mogemark, Antonios Nikitidis, Anna-Pia Palmgren, Nils Pemberton, Jens Petersen, Mio Rodrigo Blomqvist, Reed W. Smith, Matthew J. Thomas, Victoria Ullah, Christian Tyrchan, Tiiu Wennberg, Annika Westin Eriksson, Wenzhen Yang, Shuchun Zhao & Linda Öster. (2021) Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma. Journal of Medicinal Chemistry 64:12, pages 8053-8075.
Crossref
Crossref
Jingyu Zhu, Lei Jia, Yingmin Jiang, Qianqian Yu, Lei Xu, Yanfei Cai, Yun Chen, Huazhong Li, Huang Gang, Wenqing Liang & Jian Jin. (2021) Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib. Chemical Biology & Drug Design 97:6, pages 1158-1169.
Crossref
Crossref
I. MEYTS, M. DE KEUKELAERE & C. BUCCIOL. (2021) Activerende PI3Kδ-mutaties: klinische en biochemische presentatie van behandelbare primaire immuundeficiënties.. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Matthew J Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Ross Baker, Igor Bondarenko, Qingyuan Zhang, Jifeng Feng, Klaus Geissler, Mihaela Lazaroiu, Guray Saydam, Árpád Szomor, Krimo Bouabdallah, Rinat Galiulin, Toshiki Uchida, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Aruna Mehra, Barrett H Childs, Yuankai Shi & Pier Luigi Zinzani. (2021) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 22:5, pages 678-689.
Crossref
Crossref
Javier Munoz, George A. Follows & Loretta J. Nastoupil. (2021) Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Targeted Oncology 16:3, pages 295-308.
Crossref
Crossref
Jingyu Zhu, Kan Li, Li Yu, Yun Chen, Yanfei Cai, Jian Jin & Tingjun Hou. (2020) Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. Medicinal Research Reviews 41:3, pages 1599-1621.
Crossref
Crossref
Donald J. AbrahamAndrew W. Buesking, Patrick A. Mayes & Andrew P. Combs. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
30
.
Gessica Marchesini, Gianpaolo Nadali, Davide Facchinelli, Anna Candoni, Chiara Cattaneo, Luca Laurenti, Rosa Fanci, Francesca Farina, Federica Lessi, Andrea Visentin, Francesco Marchesi, Lucia Prezioso, Angelica Spolzino, Maria Chiara Tisi, Fabio Trastulli, Marika Picardi, Luisa Verga, Michelina Dargenio, Alessandro Busca & Livio Pagano. (2020) Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. British Journal of Haematology 193:2, pages 316-324.
Crossref
Crossref
Lisa Rohrbacher, Bettina Brauchle, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Veit L. Bücklein & Marion Subklewe. (2021) The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. Frontiers in Immunology 12.
Crossref
Crossref
Valerio Guarente & Paolo Sportoletti. (2021) Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. Cancers 13:6, pages 1280.
Crossref
Crossref
Johannes Schetelig, Patrice Chevallier, Michel van Gelder, Jennifer Hoek, Olivier Hermine, Ronjon Chakraverty, Paul Browne, Noel Milpied, Michele Malagola, Gerard Socié, Julio Delgado, Eric Deconinck, Ghandi Damaj, Sebastian Maury, Dietrich Beelen, Stéphanie Nguyen Quoc, Paneesha Shankara, Arne Brecht, Jiri Mayer, Mathilde Hunault-Berger, Jörg Bittenbring, Catherine Thieblemont, Stéphane Lepretre, Henning Baldauf, Liesbeth C. de Wreede, Olivier Tournilhac, Ibrahim Yakoub-Agha, Nicolaus Kröger & Peter Dreger. (2020) Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. Bone Marrow Transplantation 56:3, pages 605-613.
Crossref
Crossref
Mandana T. Manzari, Yosi Shamay, Hiroto Kiguchi, Neal Rosen, Maurizio Scaltriti & Daniel A. Heller. (2021) Targeted drug delivery strategies for precision medicines. Nature Reviews Materials 6:4, pages 351-370.
Crossref
Crossref
Max J. Gordon, Julie Huang, Rebecca J. Chan, Pankaj Bhargava & Alexey V. Danilov. (2020) Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. British Journal of Haematology 192:4, pages 720-728.
Crossref
Crossref
Ebru Aydin, Sebastian Faehling, Mariam Saleh, Laura Llaó Cid, Martina Seiffert & Philipp M. Roessner. (2021) Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. Frontiers in Immunology 11.
Crossref
Crossref
Piotr Smolewski & Tadeusz Robak. (2021) Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. Kompass Onkologie 8:2, pages 59-69.
Crossref
Crossref
Piotr Smolewski & Tadeusz Robak. (2021) Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. Acta Haematologica 144:4, pages 365-379.
Crossref
Crossref
Patrick Greve, Friederike A G Meyer-Wentrup, Victor Peperzak & Marianne Boes. (2021) Upcoming immunotherapeutic combinations for B-cell lymphoma. Immunotherapy Advances 1:1.
Crossref
Crossref
Tycel J. Phillips, Jean-Marie Michot & Vincent Ribrag. (2021) Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?. Clinical Lymphoma Myeloma and Leukemia 21:1, pages 8-20.e3.
Crossref
Crossref
Amanda J. Podolski & Rasim Gucalp. 2021. Geriatric Gastroenterology. Geriatric Gastroenterology
341
379
.
Joey L. Methot, Abdelghani Achab, Matthew Christopher, Hua Zhou, Meredeth A. McGowan, B. Wesley Trotter, Xavier Fradera, Charles A. Lesburg, Peter Goldenblatt, Armetta Hill, Dapeng Chen, Karin M. Otte, Martin Augustin, Sanjiv Shah & Jason D. Katz. (2020) Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors. ACS Medicinal Chemistry Letters 11:12, pages 2461-2469.
Crossref
Crossref
Lorenz Thurner, Sylvia Hartmann, Frank Neumann, Markus Hoth, Stephan Stilgenbauer, Ralf Küppers, Klaus-Dieter Preuss & Moritz Bewarder. (2020) Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. Frontiers in Oncology 10.
Crossref
Crossref
Ashley HanlonDanielle M. Brander. (2020) Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematology 2020:1, pages 346-356.
Crossref
Crossref
Carol Moreno. (2020) Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology 2020:1, pages 33-40.
Crossref
Crossref
Ali A. Akhiani, Alexander Hallner, Roberta Kiffin, Ebru Aydin, Olle Werlenius, Johan Aurelius, Anna Martner, Fredrik B. Thorén & Kristoffer Hellstrand. (2020) Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species. Cancer Immunology Research 8:12, pages 1532-1541.
Crossref
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Crossref
M. Sánchez Villalobos, I. Español Morales & A. Cascales Hernández. (2020) Síndromes linfoproliferativos. Medicine - Programa de Formación Médica Continuada Acreditado 13:20, pages 1133-1141.
Crossref
Crossref
Jia Li, Kevin Rockich, Brad Yuska, Gongfu Zhou, Noam Epstein, Naresh Punwani, Xuejun Chen & Swamy Yeleswaram. (2020) An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants. The Journal of Clinical Pharmacology 60:11, pages 1519-1526.
Crossref
Crossref
Yandong ShenKyle Crassini, Narjis Fatima, Michael O’DwyerMichael O’Neill, Richard I. ChristophersonStephen P. MulliganO. Giles Best. (2020) IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances 4:20, pages 5093-5106.
Crossref
Crossref
Anshul Kumar, Rohit Bhatia, Pooja Chawla, Durgadas Anghore, Vipin Saini & Ravindra K. Rawal. (2020) Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma. Anti-Cancer Agents in Medicinal Chemistry 20:10, pages 1158-1172.
Crossref
Crossref
Philipp M. Roessner & Martina Seiffert. (2020) T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?. Leukemia 34:8, pages 2012-2024.
Crossref
Crossref
Kamira Maharaj, John J. Powers, Alex Achille, Melanie Mediavilla-Varela, Wael GamalKaren L. Burger, Renee Fonseca, Kun Jiang, Hari P. MiskinDave MaryanskiAndrii Monastyrskyi, Derek R. Duckett, William R. Roush, John L. ClevelandEva Sahakian & Javier Pinilla-Ibarz. (2020) The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances 4:13, pages 3072-3084.
Crossref
Crossref
Niu Shin, Matthew Stubbs, Holly Koblish, Eddy W. Yue, Maxim Soloviev, Brent Douty, Kathy He Wang, Qian Wang, Mingming Gao, Patricia Feldman, Gengjie Yang, Leslie Hall, Michael Hansbury, Sybil O’Connor, Lynn Leffet, Robert Collins, Kamna Katiyar, Xin He, Paul Waeltz, Paul Collier, Jin Lu, Yun-Long Li, Yanlong Li, Phillip C.C. Liu, Timothy Burn, Maryanne Covington, Sharon Diamond, Dana Shuey, Alan Roberts, Swamy Yeleswaram, Greg Hollis, Brian Metcalf, Wenqing Yao, Reid Huber, Andrew Combs, Robert Newton & Peggy Scherle. (2020)
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
δ
Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
. Journal of Pharmacology and Experimental Therapeutics 374:1, pages 211-222.
Crossref
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Crossref
Barbara Rogers. (2020) B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management. Clinical Journal of Oncology Nursing 24:2, pages 199-204.
Crossref
Crossref
Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Maria Dimou, Judit Demeter, Muhit Özcan, Marina Kosinova, Krimo Bouabdallah, Franck Morschhauser, Don A. Stevens, David Trevarthen, Javier Munoz, Liana Rodrigues, Florian Hiemeyer, Ashok Miriyala, Jose Garcia‐Vargas, Barrett H. Childs & Pier Luigi Zinzani. (2020) Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study. American Journal of Hematology 95:4, pages 362-371.
Crossref
Crossref
Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven E. Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean & Thomas J. Kipps. (2019) Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 34:3, pages 787-798.
Crossref
Crossref
Lorenzo Iovino & Mazyar Shadman. (2020) Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. Current Treatment Options in Oncology 21:3.
Crossref
Crossref
Vitale, Montalbano, Salvetti, Boccellato, Griggio, Boccadoro & Coscia. (2020) Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers 12:2, pages 282.
Crossref
Crossref
Benjamin Murter & Lawrence P. Kane. (2020) Control of T lymphocyte fate decisions by PI3K signaling. F1000Research 9, pages 1171.
Crossref
Crossref
Georgios Sogkas, Ignatius Ryan Adriawan, Natalia Dubrowinskaja, Faranaz Atschekzei & Reinhold Ernst Schmidt. 2020.
109
137
.
Amanda J. Podolski & Rasim Gucalp. 2020. Geriatric Gastroenterology. Geriatric Gastroenterology
1
39
.
Antonino Carbone, Sandrine Roulland, Annunziata Gloghini, Anas Younes, Gottfried von Keudell, Armando López-Guillermo & Jude Fitzgibbon. (2019) Follicular lymphoma. Nature Reviews Disease Primers 5:1.
Crossref
Crossref
Eddy W. Yue, Yun-Long Li, Brent Douty, Chunhong He, Song Mei, Brian Wayland, Thomas Maduskuie, Nikoo Falahatpisheh, Richard B. Sparks, Padmaja Polam, Wenyu Zhu, Joseph Glenn, Hao Feng, Ke Zhang, Yanlong Li, Xin He, Kamna Katiyar, Maryanne Covington, Patricia Feldman, Niu Shin, Kathy He Wang, Sharon Diamond, Yu Li, Holly K. Koblish, Leslie Hall, Peggy Scherle, Swamy Yeleswaram, Chu-Biao Xue, Brian Metcalf, Andrew P. Combs & Wenqing Yao. (2019) INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). ACS Medicinal Chemistry Letters 10:11, pages 1554-1560.
Crossref
Crossref
Jennifer R. Brown. (2019) Phosphatidylinositol 3 Kinase δ Inhibitors. The Cancer Journal 25:6, pages 394-400.
Crossref
Crossref
Clement Chung. (2019) Current targeted therapies in lymphomas. American Journal of Health-System Pharmacy 76:22, pages 1825-1834.
Crossref
Crossref
Wei Liu, Zhen-Tang Jing, Chao-Rong Xue, Shu-Xiang Wu, Wan-Nan Chen, Xin-Jian Lin & Xu Lin. (2019) PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicology and Applied Pharmacology 381, pages 114729.
Crossref
Crossref
Gottfried von Keudell & Alison J. Moskowitz. (2019) The Role of PI3K Inhibition in Lymphoid Malignancies. Current Hematologic Malignancy Reports 14:5, pages 405-413.
Crossref
Crossref
Akihiko Oka, Yoshiyuki Mishima, Bo Liu, Jeremy W. Herzog, Erin C. Steinbach, Taku Kobayashi, Scott E. Plevy & R. Balfour Sartor. (2019) Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Cells 8:10, pages 1121.
Crossref
Crossref
Fan Fan, Dan Tan, Sen Shang, Xingjuan Wu, Jiping Zhao, Ganqiao Ran & Xiaoyun Lu. (2019)
Poly(3-hydroxybutyrate-
co
-3-hydroxyhexanoate) Biopolyester Based Nanoparticles as NVP-BEZ235 Delivery Vehicle for Tumor Targeting Therapy
. Biomacromolecules 20:9, pages 3313-3323.
Crossref
Crossref
Angela Esposito, Giulia Viale & Giuseppe Curigliano. (2019) Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer. JAMA Oncology 5:9, pages 1347.
Crossref
Crossref
Christina Buchanan, Kate Lee & Peter Shepherd. (2019) For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. Biomolecules 9:9, pages 402.
Crossref
Crossref
Cecilia C. S. Yeung & Mazyar Shadman. (2019) How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. Current Oncology Reports 21:8.
Crossref
Crossref
Krish Patel & John M. Pagel. (2019) Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports 14:4, pages 292-301.
Crossref
Crossref
Valentina Romeo, Sarah Gierke, Kyle A. Edgar & Scot D. Liu. (2019) Effects of PI3K Inhibition on Afucosylated Antibody–Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells. The Journal of Immunology 203:1, pages 137-147.
Crossref
Crossref
Jennifer L. Crombie & Jennifer R. Brown. (2019) Advances in drug‐based therapies in chronic lymphocytic leukemia and future prospects. ADVANCES IN CELL AND GENE THERAPY 2:3.
Crossref
Crossref
S. Elizabeth Franks, Andrew Getahun & John C. Cambier. (2019) A Precision B Cell–Targeted Therapeutic Approach to Autoimmunity Caused by Phosphatidylinositol 3-Kinase Pathway Dysregulation. The Journal of Immunology 202:12, pages 3381-3393.
Crossref
Crossref
Martin Špaček. (2019) Treatment of relapsed chronic lymphocytic leukemia. Onkologie 13:3, pages 107-110.
Crossref
Crossref
Aimie E. GarcesMichael J. Stocks. (2018) Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. Journal of Medicinal Chemistry 62:10, pages 4815-4850.
Crossref
Crossref
Matthew W. D. Perry, Raolat Abdulai, Mickael Mogemark, Jens Petersen, Matthew J. Thomas, Barbara Valastro & Annika Westin Eriksson. (2018) Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. Journal of Medicinal Chemistry 62:10, pages 4783-4814.
Crossref
Crossref
Laura Magnano, Sara Alonso‐Alvarez, Miguel Alcoceba, Alfredo Rivas‐Delgado, Anna Muntañola, Ferran Nadeu, Xavier Setoain, Sonia Rodríguez, Marcio Andrade‐Campos, Natalia Espinosa‐Lara, Guillermo Rodríguez, Juan Manuel Sancho, Miriam Moreno, Santiago Mercadal, Itziar Carro, Antonio Salar, Francesc Garcia‐Pallarols, Reyes Arranz, Jimena Cannata, María J. Terol, Ana I. Teruel, Ana Jiménez‐Ubieto, Antonia Rodriguez, Sonia González de Villambrosía, José L. Bello, Lourdes López, Silvana Novelli, Erik de Cabo, María E. Infante, Emilia Pardal, Silvia Monsalvo, Marcos González, Alejandro Martín, M. Dolores Caballero & Armando López‐Guillermo. (2019) Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. British Journal of Haematology 185:3, pages 480-491.
Crossref
Crossref
Marc Sorigue & Juan-Manuel Sancho. (2019) Recent landmark studies in follicular lymphoma. Blood Reviews 35, pages 68-80.
Crossref
Crossref
Cuiyun Wang, Fei Jia & Yafei Zhang. (2019) Simultaneous determination of idelalisib and its metabolite GS‐563117 in dog plasma by LC–MS/MS: Application to a pharmacokinetic study. Biomedical Chromatography 33:5.
Crossref
Crossref
Andres Forero-TorresRadhakrishnan RamchandrenAbdulraheem YacoubMichael S. WertheimWilliam J. EdenfieldPaolo CaimiMartin GutierrezLuke AkardCarolina EscobarJustin CallDaniel PerskySwaminathan IyerDouglas J. DeMarini, Li Zhou, Xuejun Chen, Fitzroy Dawkins & Tycel J. Phillips. (2019) Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 133:16, pages 1742-1752.
Crossref
Crossref
David A. Fruman. (2019) Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. Journal of Clinical Oncology 37:11, pages 932-934.
Crossref
Crossref
Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna, Scott Tetreault, Sarit E. Assouline, Jiri Mayer, Michele Merli, Scott D. Lunin, Andrew R. Pettitt, Zoltan Nagy, Olivier Tournilhac, Karem-Etienne Abou-Nassar, Michael Crump, Eric D. Jacobsen, Sven de Vos, Virginia M. Kelly, Weiliang Shi, Lori Steelman, NgocDiep Le, David T. Weaver, Stephanie Lustgarten, Nina D. Wagner-Johnston & Pier Luigi Zinzani. (2019) DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. Journal of Clinical Oncology 37:11, pages 912-922.
Crossref
Crossref
Ana Puga, Sara Lopez-Oliva, Carmen Trives, Teresa Partearroyo & Gregorio Varela-Moreiras. (2019) Effects of Drugs and Excipients on Hydration Status. Nutrients 11:3, pages 669.
Crossref
Crossref
Stalin Chellappa, Kushi Kushekhar, Ludvig A. Munthe, Geir E. Tjønnfjord, Einar M. Aandahl, Klaus Okkenhaug & Kjetil Taskén. (2019) The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function. The Journal of Immunology 202:5, pages 1397-1405.
Crossref
Crossref
Thomas Spanberger. (2018) Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls. memo - Magazine of European Medical Oncology 12:1, pages 12-16.
Crossref
Crossref
Xinrui Yuan, Hanshu Wu, Hong Bu, Jinpei Zhou & Huibin Zhang. (2019) Targeting the immunity protein kinases for immuno-oncology. European Journal of Medicinal Chemistry 163, pages 413-427.
Crossref
Crossref
Giuseppe Curigliano & Rashmi R. Shah. (2019) Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Safety 42:2, pages 247-262.
Crossref
Crossref
Antonio Cuneo, Giovanni Barosi, Romano Danesi, Stefano Fagiuoli, Paolo Ghia, Alfredo Marzano, Marco Montillo, Venerino Poletti, Pierluigi Viale & Pier Luigi Zinzani. (2018) Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. Hematological Oncology 37:1, pages 3-14.
Crossref
Crossref
Aaron Gregson, Kaitlyn Thompson, Stella E Tsirka & David L Selwood. (2019) Emerging small-molecule treatments for multiple sclerosis: focus on B cells. F1000Research 8, pages 245.
Crossref
Crossref
Marisa J. L. Aitken, Hun J. Lee & Sean M. Post. (2019) Emerging treatment options for patients with p53-pathway-deficient CLL. Therapeutic Advances in Hematology 10, pages 204062071989135.
Crossref
Crossref
Cai-Ming Chen, Wei-Bo Wu, Jian-Feng Chen & Yan Chen. (2019) Characterization of the in vitro metabolites of idelalisib in liver microsomes and interspecies comparison. Journal of Pharmaceutical and Biomedical Analysis 162, pages 249-256.
Crossref
Crossref
Tadeusz Robak. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
107
119
.
Ian W. FlinnPeter HillmenMarco MontilloZsolt NagyÁrpád IllésGabriel EtienneJulio DelgadoBryone J. KussConstantine S. TamZoltán GasztonyiFritz OffnerScott LuninFrancesco BoschMatthew S. DavidsNicole LamannaUlrich JaegerPaolo GhiaFlorence CymbalistaCraig A. PortellAlan P. SkarbnikAmanda F. CashenDavid T. WeaverVirginia M. KellyBarry TurnbullStephan Stilgenbauer. (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 132:23, pages 2446-2455.
Crossref
Crossref
Babina Gosangi, Matthew Davids, Bhanusupriya Somarouthu, Francesco Alessandrino, Angela Giardino, Nikhil Ramaiya & Katherine Krajewski. (2018) Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. Cancer Imaging 18:1.
Crossref
Crossref
Barbara Eichhorst, Michael Hallek & Valentin Goede. (2018) Management of unfit elderly patients with chronic lymphocytic leukemia. European Journal of Internal Medicine 58, pages 7-13.
Crossref
Crossref
Gail D. Rowan, Christine V. Carrington & Jim Siderov. (2018) Overview of idelalisib for pharmacists. Journal of Pharmacy Practice and Research 48:6, pages 543-549.
Crossref
Crossref
Jennifer R. Brown. (2018) Relapsed CLL: sequencing, combinations, and novel agents. Hematology 2018:1, pages 248-255.
Crossref
Crossref
Ofir Moreno, Todd Butler, Vanessa Zann, Ashley Willson, Pui Leung & Alyson Connor. (2018) Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers. Clinical Therapeutics 40:11, pages 1855-1867.
Crossref
Crossref
Benjamin W. Teh, Constantine S. Tam, Sasanka Handunnetti, Leon J. Worth & Monica A. Slavin. (2018) Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Blood Reviews 32:6, pages 499-507.
Crossref
Crossref
Susan O'Brien, Manish Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Pierluigi Porcu, Jeffrey Jones, Jan Burger, Nitin Jain, Kerstin Allen, Kerrie Faia, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly & Ian Flinn. (2018) Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal of Hematology 93:11, pages 1318-1326.
Crossref
Crossref
Paolo Strati, Alessandra Ferrajoli, William G. Wierda, Nitin Jain, Philip A. Thompson, Susan M. O’Brien, Katy Rezvani, Hagop M. Kantarjian, Jan A. Burger, Christina O. Hinojosa, Michael J. Keating & Zeev Estrov. (2018) Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32:10, pages 2278-2281.
Crossref
Crossref
Laura A. Tang, Brianne N. Dixon, Kathryn T. Maples, Kristen M. Poppiti & Tim J. Peterson. (2018) Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:10, pages 1058-1067.
Crossref
Crossref
Cecilia CS Yeung, David M Hockenbery, Maria Westerhoff, Steven E Coutre, Ruth H Sedlak, Ronald L Dubowy, Veerendra Munugalavadla, Kerry Taylor & Francesc Bosch. (2018) Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. Future Oncology 14:22, pages 2265-2277.
Crossref
Crossref
Talal Hilal, Juan C. Gea-Banacloche & Jose F. Leis. (2018) Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews 32:5, pages 387-399.
Crossref
Crossref
Anna H. Schuh, Nilima Parry‐Jones, Niamh Appleby, Adrian Bloor, Claire E. Dearden, Christopher Fegan, George Follows, Christopher P. Fox, Sunil Iyengar, Ben Kennedy, Helen McCarthy, Helen M. Parry, Piers Patten, Andrew R. Pettitt, Ingo Ringshausen, Renata Walewska & Peter Hillmen. (2018) Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology 182:3, pages 344-359.
Crossref
Crossref
Anthea C. Peters & Andrei Fagarasanu. (2018) Novel agents in the Canadian therapeutic landscape of chronic lymphocytic leukemia. Oncology Signaling 1:1, pages 7-10.
Crossref
Crossref
Joanna Rhodes, Anthony Mato & Jeff P. Sharman. (2018) Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Current Oncology Reports 20:6.
Crossref
Crossref
Saige L Pompura & Margarita Dominguez-Villar. (2018) The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. Journal of Leukocyte Biology 103:6, pages 1065-1076.
Crossref
Crossref
Maria Bhatti, Thomas Ippolito, Cory Mavis, Juan Gu, Mitchell S. Cairo, Megan S. Lim, Francisco Hernandez-Ilizaliturri & Matthew J. Barth. (2018) Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget 9:31, pages 21820-21830.
Crossref
Crossref
Mitchell E. Hughes & Jennifer Gill. (2018) Primer on Chronic Lymphocytic Leukemia: Part II. The Journal for Nurse Practitioners 14:4, pages 309-315.e2.
Crossref
Crossref
Jacqueline C Barrientos. (2018) Can umbralisib bring PI3Kδ out of the shadows?. The Lancet Oncology 19:4, pages 432-434.
Crossref
Crossref
Howard A BurrisIIIIII, Ian W Flinn, Manish R Patel, Timothy S Fenske, Changchun Deng, Danielle M Brander, Martin Gutierrez, James H Essell, John G Kuhn, Hari P Miskin, Peter Sportelli, Michael S Weiss, Swaroop Vakkalanka, Michael R Savona & Owen A O'Connor. (2018) Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. The Lancet Oncology 19:4, pages 486-496.
Crossref
Crossref
Xiaoyan Liu, Yan Xu, Qing Zhou, Minjiang Chen, Yu Zhang, Hongge Liang, Jing Zhao, Wei Zhong & Mengzhao Wang. (2018) PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncology 14:7, pages 665-674.
Crossref
Crossref
Arnon P. Kater, Sanne H. Tonino, Marjolein Spiering, Martine E. D. Chamuleau, Roberto Liu, Adeboye Henry Adewoye, Jie Gao, Lyndah Dreiling, Yan Xin, Jeanette K. Doorduijn & Marie José Kersten. (2018) Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer Journal 8:2.
Crossref
Crossref
Sabina Kersting, Suzanne I.M. Neppelenbroek, Hein P.J. Visser, Michel van Gelder, Mark-David Levin, Rogier Mous, Ward Posthuma, Hanneke M. van der Straaten & Arnon P. Kater. (2018) Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clinical Lymphoma Myeloma and Leukemia 18:1, pages 52-57.
Crossref
Crossref
M. Schmidt-Hieber, J. Bierwirth, D. Buchheidt, O. A. Cornely, M. Hentrich, G. Maschmeyer, E. Schalk, J. J. Vehreschild & Maria J. G. T. Vehreschild. (2017) Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology 97:1, pages 31-49.
Crossref
Crossref
Katja Zirlik & Hendrik Veelken. 2018. Small Molecules in Hematology. Small Molecules in Hematology
243
264
.
Inhye E. Ahn & Matthew S. Davids. (2017) Safety profiles of novel agent therapies in CLL. Hematology 2017:1, pages 354-357.
Crossref
Crossref
Thomas Gryc, Florian Putz, Nicole Goerig, Sonia Ziegler, Rainer Fietkau, Luitpold V. Distel & Barbara Schuster. (2017) Idelalisib may have the potential to increase radiotherapy side effects. Radiation Oncology 12:1.
Crossref
Crossref
Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack & Tamar Tadmor. (2017) The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 863-869.
Crossref
Crossref
Marisa A. Fuse, Stephani Klingeman Plati, Sarah S. Burns, Christine T. Dinh, Olena Bracho, Denise Yan, Rahul Mittal, Rulong Shen, Julia N. Soulakova, Alicja J. Copik, Xue Zhong Liu, Fred F. Telischi, Long-Sheng Chang, Maria Clara Franco & Cristina Fernandez-Valle. (2017) Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics 16:11, pages 2387-2398.
Crossref
Crossref
Bernard L Marini, Lisa Samanas & Anthony J Perissinotti. (2016) Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. Journal of Oncology Pharmacy Practice 23:7, pages 502-517.
Crossref
Crossref
B Yigit, N Wang, S-S Chen, N Chiorazzi & C Terhorst. (2017) Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells. Leukemia 31:10, pages 2273-2276.
Crossref
Crossref
Stephanie T. ChangChristine O. MeniasMeghan G. LubnerVincent M. MellnickAmy K. HaraTerry S. Desser. (2017) Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. RadioGraphics 37:5, pages 1461-1482.
Crossref
Crossref
Massimiliano Galeone & Emiliano Antiga. (2017) Multiple mucosal ulcerations caused by idelalisib. International Journal of Dermatology 56:9, pages e180-e181.
Crossref
Crossref
Clare Harris & Clare R. Sander. (2017) Late respiratory effects of cancer treatment. Current Opinion in Supportive & Palliative Care 11:3, pages 197-204.
Crossref
Crossref
C.L. Batlevi & A. Younes. (2017) Revival of PI3K inhibitors in non-Hodgkin’s lymphoma. Annals of Oncology 28:9, pages 2047-2049.
Crossref
Crossref
M. Dreyling, F. Morschhauser, K. Bouabdallah, D. Bron, D. Cunningham, S.E. Assouline, G. Verhoef, K. Linton, C. Thieblemont, U. Vitolo, F. Hiemeyer, M. Giurescu, J. Garcia-Vargas, I. Gorbatchevsky, L. Liu, K. Koechert, C. Peña, M. Neves, B.H. Childs & P.L. Zinzani. (2017) Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology 28:9, pages 2169-2178.
Crossref
Crossref
Jon E. Arnason & Jennifer R. Brown. (2017) Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Current Oncology Reports 19:9.
Crossref
Crossref
David A. Fruman, Honyin Chiu, Benjamin D. Hopkins, Shubha Bagrodia, Lewis C. Cantley & Robert T. Abraham. (2017) The PI3K Pathway in Human Disease. Cell 170:4, pages 605-635.
Crossref
Crossref
C. Shustik, I. Bence-Bruckler, R. Delage, C. J. Owen, C. L. Toze & S. Coutre. (2017) Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Annals of Hematology 96:7, pages 1185-1196.
Crossref
Crossref
Matthew W. D. Perry, Karin Björhall, Britta Bonn, Johan Carlsson, Yunhua Chen, Anders Eriksson, Linda Fredlund, Hai’e Hao, Neil S. Holden, Kostas Karabelas, Helena Lindmark, Feifei Liu, Nils Pemberton, Jens Petersen, Sandra Rodrigo Blomqvist, Reed W. Smith, Tor Svensson, Ina Terstiege, Christian Tyrchan, Wenzhen Yang, Shuchun Zhao & Linda Öster. (2017) Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration. Journal of Medicinal Chemistry 60:12, pages 5057-5071.
Crossref
Crossref
Jennifer Edelmann & John G. Gribben. (2017)
Managing Patients With
TP53
-Deficient Chronic Lymphocytic Leukemia
. Journal of Oncology Practice 13:6, pages 371-377.
Crossref
Crossref
Ajay K. GopalBrad S. KahlChristopher R. FlowersPeter MartinStephen M. AnsellEsteban Abella-DominicisBrian KohWei YePaul M. Barr, Gilles A. Salles & Jonathan W. Friedberg. (2017) Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood 129:22, pages 3037-3039.
Crossref
Crossref
Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Franck Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson & Julie Vose. (2016) The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology 14:6, pages 335-346.
Crossref
Crossref
Allison Rosenthal. (2017) Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports 12:3, pages 207-216.
Crossref
Crossref
Displaying 200 of 239 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list